Avadel Pharmaceuticals plc (AVDL)

Market Cap	1.81B
Revenue (ttm)	221.08M
Net Income (ttm)	-2.92M
Shares Out	97.40M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	44.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,800,923
Open	18.55
Previous Close	18.56
Day's Range	18.54 - 18.60
52-Week Range	6.38 - 18.65
Beta	1.63
Analysts	Buy
Price Target	18.94 (+2.05%)
Earnings Date	Nov 12, 2025

About AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 7, 1996
• Employees: 188
• Stock Exchange: NASDAQ
• Ticker Symbol: AVDL
• Website: https://www.avadel.com

Financial Performance

In 2024, Avadel Pharmaceuticals's revenue was $169.12 million, an increase of 504.79% compared to the previous year's $27.96 million. Losses were -$48.83 million, -69.53% less than in 2023.

Analyst Summary

According to 10 analysts, the average rating for AVDL stock is "Buy." The 12-month stock price target is $18.94, which is an increase of 2.05% from the latest price.

Price Target

$18.94

(2.05% upside)

Analyst Consensus: Buy